Um, it is absolutely the same Bioelectronics Corporation. I agree Electrome presents a great opportunity for BIEL; it also looks like a last chance gasp. Ken wants an FDA approved product right now - and he found one. Kelly has to be both thrilled and grateful. Staelin helped her build a strong deal as well I am sure - as strong as BIEL could negotiate at least. Ken needed the product, and Kelly needed sales. Perfect.
That, however, does not change the share structure, nor the mounting losses, nor future uncertainty, or anything else for that matter. Ken now has to deliver on his plan, and while it's a good one (maybe a great one?), it will be a challenge. Again though - valuations that make no sense - .04/.05/.09 by year end? Not happening IMO. BTW - keep in mind that if/when the PPS starts to climb, people will sell and take profits. How much people sell, and at what price, could very much curtail any wild run-ups to the prices you mention. You have already seen how the last week didn't move the needle one bit.
Same BIEL, same challenges. Long way to go yet.